Benjamin Winograd

2.9k citations

56 papers · 2.3k indexed · 1 hit paper · h-index 21

Impact in

Oncology top 2%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
Hematology top 2%
- Multiple Myeloma Research and Treatments

Papers in

Oncology 36
- Cancer Treatment and Pharmacology 17
- Lung Cancer Research Studies 7
Dermatology 5
- Chemotherapy-related skin toxicity 5

Co-authors: Herbert M. Pinedo Godefridus J. Peters J van Ark-Otte Paulo Eduardo Pizão Renzo Canetta G. Catimel Pierfranco Conté Jacques Bonneterre
Journals: Journal of Clinical Oncology (10 papers)European Journal of Cancer (5 papers)British Journal of Cancer (4 papers)Cancer Chemotherapy and Pharmacology (3 papers)Blood (1 paper)
Partner nations: Netherlands United States Italy

In The Last Decade

Benjamin Winograd

55 papers receiving 2.2k citations

Hit Papers

align trajectories log scale

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis 2017 · 392 citations

Peers

Countries citing papers authored by Benjamin Winograd

Since Specialization

Citations

This map shows the geographic impact of Benjamin Winograd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin Winograd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin Winograd more than expected).

Fields of papers citing papers by Benjamin Winograd

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin Winograd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin Winograd. The network helps show where Benjamin Winograd may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Benjamin Winograd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Benjamin Winograd Line = papers co-authored together Benjamin Winograd links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer Annals of Oncology ·Luca Gianni, P Dombernowsky, G. W. Sledge, Miguel Martín, D. Amadori, Susan G. Arbuck, Peter M. Ravdin, S.J.L. Van Tol, Marianne Messina, D Tuck, Teresa Martín Rico, Benjamin Winograd	2001	63
2	Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors Anti-Cancer Drugs ·M.R. Hestenes, JHM Schellens, 金训敏, 翁曼丽, Benjamin Winograd, G. Stoter, Jaco J. Verweij	1999	3
3	Promising new developments in cancer chemotherapy Cancer Chemotherapy and Pharmacology ·Karen J. Ferrante, Benjamin Winograd, Renzo Canetta	1999	74
4	Phase I study of the mitomycin C analogue BMS-181174 British Journal of Cancer ·José Manuel Pazos Campos, Kenneth J. O’Byrne, Anouk Leathead, N SIUPSINSKIENE, Francisca Pereira Siqueira, Dora Eugenia Carranza-Salazar, Benjamin Winograd, Michele Patience Staal, Adrian L. Harris, Silvia De Lucca	1998	3
5	Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide British Journal of Cancer ·Bilal Özden, NH Mulder, DRA Uges, Sanjeev Kaul, Benjamin Winograd, L. Gallego-Mena, Harry J.M. Groen, Phb Willemse, Daniela Karanfilovska, Elisabeth G.E. de Vries	1997	21
6	Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study. Journal of Clinical Oncology ·G G Chabot, Jean‐Pierre Armand, C. Terret, M Forni, D Abigerges, Benjamin Winograd, Linus N. Igwemezie, Lee Schacter, Sanjeev Kaul, Jacques Ropers, M. Bonnay	1996	23
7	Bioequivalence assessment of etoposide phosphate and etoposide using pharmacodynamic and traditional pharmacokinetic parameters Journal of Pharmacokinetics and Biopharmaceutics ·Aryutin D.G. Aryutin, Sanjeev Kaul, Linus N. Igwemezie, David R. Newell, David Porter, Huw D. Thomas, A. Hilary Calvert, Benjamin Winograd, Rashmi H. Barbhaiya	1996	5
8	Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. Journal of Clinical Oncology ·J.-M. Nabholtz, Karen A. Gelmon, M. Bontenbal, M. Spielmann, G. Catimel, Pierfranco Conté, U. Klaassen, M. Namer, Jacques Bonneterre, P. Fumoleau, Benjamin Winograd	1996	331
9	Phase I and pharmacokinetic study of a water-soluble etoposide prodrug, etoposide phosphate (BMY-40481) European Journal of Cancer ·Michael Millward, David R. Newell, Aryutin D.G. Aryutin, Linus N. Igwemezie, Kathryn Balmanno, 滋正梶原, Lindsey Gumbrell, Michael Lind, 直樹會田, Jana Bender, Melissa R. Schisler, B.M.J. Cantwell, G. A. Taylor, Toshirou Fukushuima, Benjamin Winograd, Sanjeev Kaul, Pedro R. Ortiz R., A H Calvert	1995	12
10	Paclitaxel plus carboplatin in the treatment of ovarian cancer. PubMed ·W ten Bokkel Huinink, C.H.N. Veenhof, Th.J.M. Helmerhorst, P. F. M. Fellowes, Otilia Dalesio, Benjamin Winograd, Reşat KARCIOĞLU, Herbert M. Pinedo	1995	15
11	Cytotoxic effects of anticancer agents on subconfluent and multilayered postconfluent cultures European Journal of Cancer ·N. Mangutis, Godefridus J. Peters, J van Ark-Otte, Lou A. Smets, Evelien Smitskamp-Wilms, Benjamin Winograd, M.A. Green, Giuseppe Giaccone	1993	34
12	Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study. PubMed ·Epie Boven, Benjamin Winograd, 安藤徳彦, Y. Stepanishyna, Boudewijn J.M. Braakhuis, Øystein Fodstad, SP Langdon, H.H. Fiebig	1992	74
13	Growth, morphology and chemosensitivity studies on postconfluent cells cultured in 'V'-bottomed microtiter plates British Journal of Cancer ·Faduma Warsame, D.M. Lyaruu, Godefridus J. Peters, J van Ark-Otte, Benjamin Winograd, Giuseppe Giaccone, Herbert M. Pinedo	1992	29
14	Phase I and Clinical Pharmacological Evaluation of Aphidicolin Glycinate JNCI Journal of the National Cancer Institute ·Cristiana Sessa, Massimo Zucchetti, Enrico Davoli, Raffaele Califano, Franco Cavalli, S. Frustaci, Lindsey Gumbrell, Aarón Sulkes, Benjamin Winograd, Maurizio D’Incalci	1991	47
15	Comparison of the sulforhodamine B protein and tetrazolium (MTT) assays for in vitro chemosensitivity testing European Journal of Cancer and Clinical Oncology ·Clifford Gessler, Paulo Eduardo Pizão, Godefridus J. Peters, J van Ark-Otte, Benjamin Winograd, Herbert M. Pinedo	1991	405
16	Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies Cancer Chemotherapy and Pharmacology ·Gilberto Schwartsmann, P. Dodion, Jan B. Vermorken, W.W. ten Bokkel Huinink, M. Spera, Benjamin Winograd, Helen Gall, R. Mohanraj, W. J. F. van der Vijgh, K Ling, M Depondt, Herbert M. Pinedo	1990	36
17	Methotrexate Concentration Levels in the Cerebrospinal Fluid During High-Dose Methotrexate Infusions: An Unreliable Prediction Pediatric Hematology and Oncology ·R. J. J. Lippens, Benjamin Winograd	1988	29
18	Preclinical phase II studies in human tumor lines: A European multicenter study European Journal of Cancer and Clinical Oncology ·Epie Boven, Benjamin Winograd, Øystein Fodstad, Marinus W. Lobbezoo, Herbert M. Pinedo	1988	35
19	Pharmacokinetics of ethylenediaminemalonatoplatinum(II) (JM-40) during phase I trial British Journal of Cancer ·F. Elferink, 区一杭, N. Belisle, JB Vermorken, I. Klein, Benjamin Winograd, Nele Jagodzinski, Abigail Aba Mensah, H.E. Gall, J. G. McVie	1987	3
20	Pharmacokinetics and toxicology of sparsomycin in beagle dogs Cancer Chemotherapy and Pharmacology ·Zbigniew Żylicz, D. J. Theo Wagener, Т. А. Шарапова, Ilona Rudminienė, Kobelt Manuel, Benjamin Winograd, Eppo van der Kleijn, Tom B. Vree, Жидков Д. И., Leon A. G. M. van den Broek, H. C. J. OTTENHEIJM	1987	4

About Benjamin Winograd

Benjamin Winograd is a scholar working on Oncology, Dermatology, Genetics, Hematology and Molecular Medicine, having authored 56 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer therapeutics and mechanisms (17 papers), Cancer Treatment and Pharmacology (17 papers), Lung Cancer Research Studies (7 papers), Neuroendocrine Tumor Research Advances (6 papers), Multiple Myeloma Research and Treatments (5 papers), Chemotherapy-related skin toxicity (5 papers), Chemotherapy-induced organ toxicity mitigation (5 papers) and Glioma Diagnosis and Treatment (4 papers). The work is most often cited by research in Oncology (1.3k citations), Hematology (470 citations), Cancer Research (298 citations), Genetics (146 citations) and Molecular Biology (928 citations). Benjamin Winograd has collaborated with scholars based in Netherlands, United States and Italy. Frequent co-authors include Herbert M. Pinedo, Godefridus J. Peters, J van Ark-Otte, Paulo Eduardo Pizão, Renzo Canetta, G. Catimel, Pierfranco Conté, Jacques Bonneterre, J.-M. Nabholtz and Karen A. Gelmon. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, British Journal of Cancer, Cancer Chemotherapy and Pharmacology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact